Waters to Acquire Becton Dickinson's Diagnostics Unit in $17.5 Billion Merger
Originally Published 6 months ago — by Reuters
Waters Corp is acquiring a Becton Dickinson bioscience and diagnostics unit in a $17.5 billion stock-and-cash deal, aiming to expand its presence in clinical and diagnostic markets, while Becton Dickinson exits a tariff-sensitive segment to focus on core medtech. The deal, structured through a Reverse Morris Trust, will result in Waters owning 61% of the new company, with Becton Dickinson shareholders holding 39%, but has faced skepticism from investors due to execution risks.